Published in Allergy on November 20, 2013
IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function. PLoS One (2016) 1.39
Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice. Br J Pharmacol (2014) 0.79
IL-31 is overexpressed in lichen planus but its level does not correlate with pruritus severity. J Immunol Res (2015) 0.77
Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17. Br J Pharmacol (2016) 0.77
Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis. Int J Mol Sci (2016) 0.76
Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments. Int J Mol Sci (2017) 0.75
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Different requirements for EDS1 and NDR1 by disease resistance genes define at least two R gene-mediated signaling pathways in Arabidopsis. Proc Natl Acad Sci U S A (1998) 4.70
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
Rapid identification of methicillin-resistant Staphylococcus aureus and simultaneous species confirmation using real-time fluorescence PCR. J Clin Microbiol (2000) 3.82
CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ (1996) 2.10
Mast cells as sentinels of innate immunity. Curr Opin Immunol (1999) 1.85
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (1997) 1.78
EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy (2009) 1.65
Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology (2006) 1.65
Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57
A quantitative description of the ground-state wave function of Cu(A) by X-ray absorption spectroscopy: comparison to plastocyanin and relevance to electron transfer. J Am Chem Soc (2001) 1.55
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Embolization of biologic glue during repair of aortic dissection. Ann Thorac Surg (1995) 1.52
How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51
Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A (2001) 1.43
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
Fatal recurrent subarachnoid hemorrhage after complete endovascular aneurysm occlusion. AJNR Am J Neuroradiol (2006) 1.40
The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy (2009) 1.39
Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35
NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. Biochemistry (1999) 1.33
Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev (1998) 1.31
p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27
What is the physiological function of mast cells? Exp Dermatol (2003) 1.26
A simultaneous (15)N, (1)H- and (13)C, (1)H-HSQC with sensitivity enhancement and a heteronuclear gradient echo. J Biomol NMR (1995) 1.25
Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol (1998) 1.25
Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol (2006) 1.24
Nitric oxide synthase localization in the rat neutrophils: immunocytochemical, molecular, and biochemical studies. J Leukoc Biol (2005) 1.22
Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21
p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
Re-engineering the toilet for sustainable waste water management. Environ Sci Technol (2001) 1.14
Rupatadine in allergic rhinitis and chronic urticaria. Allergy (2008) 1.13
Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol (2010) 1.12
Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model. J Antibiot (Tokyo) (1982) 1.11
Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry (2008) 1.08
Penumbra system: a novel mechanical thrombectomy device for large-vessel occlusions in acute stroke. AJNR Am J Neuroradiol (2009) 1.07
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07
Mast cell involvement in murine hair growth. Dev Biol (1994) 1.06
Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene (2007) 1.04
Mast cells as initiators of immunity and host defense. Exp Dermatol (2001) 1.02
Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis (2009) 1.01
In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob Agents Chemother (2000) 1.01
Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy (2009) 1.00
Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system. J Exp Med (1997) 1.00
PLUSH TACSY: Homonuclear planar TACSY with two-band selective shaped pulses applied to C(α),C' transfer and C (β),C (aromatic) correlations. J Biomol NMR (1996) 0.99
A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol (2000) 0.99
Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy (2009) 0.98
Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics (1991) 0.98
Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy (2010) 0.97
Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as "epitheliotrophins" in murine skin. Lab Invest (1999) 0.97
Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol (2007) 0.97
The role of innate immunity in asthma: leads and lessons from mouse models. Allergy (2007) 0.96
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96
Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br J Dermatol (2003) 0.95
Reconstruction of major column defects and pelvic discontinuity in revision total hip arthroplasty. J Arthroplasty (2000) 0.95
Anti-diarrhoeal evaluation of Clerodendrum phlomidis Linn. leaf extract in rats. J Ethnopharmacol (1999) 0.95
EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy (2012) 0.95
A new role for neurotrophin-3: involvement in the regulation of hair follicle regression (catagen). Am J Pathol (1998) 0.94
The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol (2009) 0.94
Planar embryos have poor prognosis in terms of blastocyst formation and implantation. Reprod Biomed Online (2012) 0.94
Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy (2010) 0.94
Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther (2004) 0.94
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2002) 0.94
[Autoreactive urticaria and autoimmune urticaria]. Hautarzt (2004) 0.93
High incidence of parvovirus B19 DNA in synovial tissue of patients with undifferentiated mono- and oligoarthritis. Clin Rheumatol (2000) 0.93
A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control. FASEB J (1999) 0.93
Hair cycle-dependent changes in adrenergic skin innervation, and hair growth modulation by adrenergic drugs. J Invest Dermatol (1999) 0.93
Coccidioidomycosis in Tulare County, California, 1991: reemergence of an endemic disease. J Med Vet Mycol (1998) 0.92
Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med (1998) 0.92
A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin Exp Dermatol (2013) 0.92
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia (2012) 0.92
Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy (2008) 0.92
Neuro-imaging of cerebral ischemic stroke. J Neuroradiol (2008) 0.91
Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy (2008) 0.91
Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res (1995) 0.91
Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol (2006) 0.90